3PBIOVIAN has appointed Ponchi Kantt-Neaz as Global Executive Business Director, marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
CDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing authorization from Lithuania’s State Medicines Control Agency within six months.
Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee on 1 January 2027. In the newly created role, she will lead Strategic Enterprise Account Management, Global Marketing and Commercial Excellence. She´s been with Lonza before her CEO role at Celonic for the last three years.
Consolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.
Ariane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
Dr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
Europe continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
Evonik is investing €80 million in its fermentation plant in Slovakia, pushing the Group’s structural transformation forward with a major investment in biotechnology. Alongside spider‑silk proteins from Amsilk, the site is set to offer a broader CDMO portfolio for the pharmaceutical industry.
3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
CDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.
Lonza Group
Samsung Biologics
Ardena
Rezon Bio
3PBIOVIAN
Evonik Industries AG
Lonza Group